Betel nut chewing and the risk of chronic kidney disease: evidence from a meta-analysis

M Wang, SY Yu, Z Lv, Y Yao - International urology and nephrology, 2018 - Springer
Purpose To investigate and quantify the potential association between betel nut chewing
and the risk of chronic kidney disease (CKD). Methods We searched five online databases …

Role of MicroRNA‐103a targeting ADAM10 in abdominal aortic aneurysm

T Jiao, Y Yao, B Zhang, DC Hao, QF Sun… - BioMed research …, 2017 - Wiley Online Library
MicroRNAs (miRNAs) are deregulated in various vascular ailments including abdominal
aortic aneurysm (AAA). MiR‐103 is involved in vascular, metabolic, and malignant diseases …

The ADAM17-directed inhibitory antibody MEDI3622 antagonizes radiotherapy-induced VEGF release and sensitizes non–small cell lung cancer for radiotherapy

F Tschanz, S Bender, I Telarovic, V Waller… - Cancer Research …, 2021 - AACR
The cellular response to ionizing radiation (IR) depends on tumor cell and
microenvironmental factors. Here, we investigated the role of IR-induced ADAM17 matrix …

ADAM10 and Neprilysin level decreases in immune cells of mice bearing metastatic breast carcinoma: Possible role in cancer inflammatory response

N Erin, Ö Akdeniz - International Immunopharmacology, 2024 - Elsevier
Objective and design ADAM10 and Neprilysin, proteases, play critical role in inflammatory
disease, however their role in cancer immune response is not clear. We here evaluated …

Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis

ZG Sargın, N Erin, G Tazegul, GÖ Elpek, B Yıldırım - PLoS One, 2017 - journals.plos.org
Neprilysin (NEP, CD10) acts to limit excessive inflammation partly by hydrolyzing
neuropeptides. Although deletion of NEP exacerbates intestinal inflammation in animal …

The role of CD200 in kidney cancer immune evasion

G Davies - 2023 - orca.cardiff.ac.uk
Kidney cancer is the 7th most common cancer type in the UK, with around 13,300 new cases
diagnosed every year, accounting for 4% of new cancer cases and 3% of all cancer deaths …